Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANIRUDHA DASGUPTA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841298387
CMS profile
129356
Location
KINGWOOD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$6,851.12

162 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
ARRAY BIOPHARMA INC $1,909.87 2
Exelixis Inc. $1,700.92 4
Amgen Inc. $301.35 14
Novartis Pharmaceuticals Corporation $270.17 17
MorphoSys, US Inc. $233.89 4
AstraZeneca Pharmaceuticals LP $205.87 8
Janssen Biotech, Inc. $184.49 7
Seagen Inc. $183.11 6
GlaxoSmithKline, LLC. $154.86 8
E.R. Squibb & Sons, L.L.C. $151.37 10
GENZYME CORPORATION $146.39 8
EISAI INC. $126.75 5
Merck Sharp & Dohme Corporation $114.70 6
Dova Pharmaceuticals $82.71 5
Boehringer Ingelheim Pharmaceuticals, Inc. $69.40 4
SANOFI-AVENTIS U.S. LLC $68.90 3
Bayer HealthCare Pharmaceuticals Inc. $68.83 4
Celgene Corporation $68.11 4
Taiho Oncology, Inc. $67.01 4
PFIZER INC. $62.81 4
Janssen Pharmaceuticals, Inc $47.82 3
Pharmacyclics LLC, An AbbVie Company $43.14 2
Deciphera Pharmaceuticals Inc. $43.13 2
Alnylam Pharmaceuticals Inc. $41.27 2
Acceleron Pharma, Inc. $40.96 2
Lilly USA, LLC $37.87 2
Kite Pharma, Inc. $37.31 2
Ipsen Biopharmaceuticals, Inc $36.12 2
Karyopharm Therapeutics Inc. $36.00 2
Astellas Pharma US Inc $34.62 2
Daiichi Sankyo Inc. $33.30 2
TerSera Therapeutics LLC $29.83 1
Myovant Sciences Inc. $27.66 1
JAZZ PHARMACEUTICALS INC. $24.41 1
Nestle HealthCare Nutrition Inc. $23.71 1
Takeda Pharmaceuticals U.S.A., Inc. $22.84 1
BOSTON SCIENTIFIC CORPORATION $19.93 1
Blueprint Medicines Corporation $17.97 1
AbbVie Inc. $17.11 1
Agios Pharmaceuticals, Inc. $17.00 1
Regeneron Healthcare Solutions, Inc. $16.93 1
Incyte Corporation $16.37 1
Rigel Pharmaceuticals, Inc. $14.31 1

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANIRUDHA DASGUPTA

NPI 1841298387 · CMS profile ID 129356

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

KINGWOOD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841298387?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANIRUDHA DASGUPTA, NPI 1841298387, CMS profile ID 129356. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841298387?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANIRUDHA DASGUPTA, NPI 1841298387, CMS profile ID 129356. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841298387?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANIRUDHA DASGUPTA, NPI 1841298387, CMS profile ID 129356, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1841298387?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

162 matching records · $6,851.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 162 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 162.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $13.2309/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830068885 CMS
Seagen Inc. $21.2408/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832172509 CMS
E.R. Squibb & Sons, L.L.C. $13.4708/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783463405 CMS
Nestle HealthCare Nutrition Inc. $23.7108/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820887269 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.7108/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763570590 CMS
GENZYME CORPORATION $17.0408/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843482739 CMS
Celgene Corporation $18.6908/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783684831 CMS
Dova Pharmaceuticals $12.6308/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849747333 CMS
Amgen Inc. $60.9908/20/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826527873 CMS
Amgen Inc. $15.2308/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825146409 CMS
GENZYME CORPORATION $17.3308/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843482737 CMS
AstraZeneca Pharmaceuticals LP $16.0508/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829859681 CMS
Janssen Biotech, Inc. $24.8508/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788739725 CMS
Taiho Oncology, Inc. $18.1308/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843379073 CMS
Amgen Inc. $11.3108/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826294629 CMS
Seagen Inc. $19.2208/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832172513 CMS
Deciphera Pharmaceuticals Inc. $24.5008/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826794833 CMS
E.R. Squibb & Sons, L.L.C. $12.3308/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783463397 CMS
GlaxoSmithKline, LLC. $26.1108/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803159659 CMS
Janssen Pharmaceuticals, Inc $14.8008/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788739731 CMS
Novartis Pharmaceuticals Corporation $20.0208/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812651701 CMS
E.R. Squibb & Sons, L.L.C. $18.1908/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783463383 CMS
Eisai Inc. $22.1907/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817971343 CMS
ARRAY BIOPHARMA INC $19.8707/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832934467 CMS
Seagen Inc. $16.4007/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832172459 CMS
Amgen Inc. $29.0907/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826294649 CMS
Astellas Pharma US Inc $17.3207/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821295279 CMS
GENZYME CORPORATION $19.3807/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843482727 CMS
Janssen Pharmaceuticals, Inc $17.2107/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788739729 CMS
Merck Sharp & Dohme Corporation $15.9807/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848342921 CMS
ARRAY BIOPHARMA INC $1,890.0007/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832892291 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5107/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763570592 CMS
GlaxoSmithKline, LLC. $32.7407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802126357 CMS
Deciphera Pharmaceuticals Inc. $18.6307/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826794829 CMS
GlaxoSmithKline, LLC. $0.4106/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802843198 CMS
Taiho Oncology, Inc. $16.2906/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843379049 CMS
Merck Sharp & Dohme Corporation $25.0006/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848544001 CMS
E.R. Squibb & Sons, L.L.C. $15.1806/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783463257 CMS
Amgen Inc. $23.4706/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826294645 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.0806/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789087369 CMS
Novartis Pharmaceuticals Corporation $19.7406/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812651699 CMS
Acceleron Pharma, Inc. $19.9806/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843319827 CMS
MorphoSys, US Inc. $84.2106/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854734935 CMS
GlaxoSmithKline, LLC. $24.2306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801671419 CMS
Exelixis Inc. $18.2506/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838869223 CMS
Karyopharm Therapeutics Inc. $16.0306/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845783647 CMS
Lilly USA, LLC $19.3706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818947177 CMS
E.R. Squibb & Sons, L.L.C. $11.5305/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783463249 CMS
Acceleron Pharma, Inc. $20.9805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843319845 CMS
Astellas Pharma US Inc $17.3005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821295275 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,633.71 186
PY2020 $4,858.13 119
PY2021 $6,851.12 162
PY2022 $5,203.48 193
PY2023 $2,893.82 143
PY2024 $17,737.27 181
PY2025 $4,032.33 180

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,193,182.53 68
PY2024 Principal investigator $1,743,640.62 38
PY2023 Principal investigator $1,449,736.14 28
PY2022 Principal investigator $1,131,352.38 27
PY2021 Principal investigator $519,791.96 26
PY2020 Principal investigator $465,502.85 17
PY2019 Recipient $108.40 1
PY2019 Principal investigator $829,812.80 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $8,497.86 12/31/2025 Non-covered Recipient Entity
Millennium Research & Clinical Development
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927563
Principal investigator 1 BioNTech SE $1,971.15 12/19/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
BNT327 No dispute reported 06/30/2026 1249011912
Principal investigator 1 BioNTech SE $7,884.60 11/20/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
BNT327 No dispute reported 06/30/2026 1249011914
Principal investigator 1 BioNTech SE $12,564.70 11/20/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327 No dispute reported 06/30/2026 1249020583
Principal investigator 1 BioNTech SE $4,041.75 11/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
BNT327 No dispute reported 06/30/2026 1249011916
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
Texas Oncology, P. A.
BNT327-03 No dispute reported 06/30/2026 1249011918
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
Texas Oncology, P. A.
BNT327-03 No dispute reported 06/30/2026 1249011954
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,960.00 10/24/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185554256
Principal investigator 1 AstraZeneca Pharmaceuticals LP $57,718.85 10/17/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer No dispute reported 06/30/2026 1185554264
Principal investigator 1 BioNTech SE $1,459.55 09/04/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020559
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,750.00 09/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185554266
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $400.00 08/12/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233741030
Principal investigator 1 BioNTech SE $7,369.00 08/07/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020561
Principal investigator 1 BioNTech SE $325.00 08/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-07 No dispute reported 06/30/2026 1249014137
Principal investigator 1 BioNTech SE $5,421.30 07/04/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020557
Principal investigator 1 AstraZeneca UK Limited $6,500.00 06/27/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) No dispute reported 06/30/2026 1185554260
Principal investigator 1 BioNTech SE $4,466.00 06/24/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020509
Principal investigator 1 BioNTech SE $1,111.80 06/19/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020485
Principal investigator 1 BioNTech SE $41,729.05 06/19/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020487
Principal investigator 1 BioNTech SE $4,466.00 06/19/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020491
Principal investigator 1 BioNTech SE $1,111.80 06/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020483
Principal investigator 1 BioNTech SE $3,676.25 05/28/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020481
Principal investigator 1 BioNTech SE $12,959.95 05/27/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020479
Principal investigator 1 BioNTech SE $9,351.00 05/27/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020489
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,760.00 05/22/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233741028
Principal investigator 1 BioNTech SE $9,351.00 05/15/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020507
Principal investigator 1 AstraZeneca Pharmaceuticals LP $61,737.37 05/07/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH & DEVELOPMENT, LLC
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185554250
Principal investigator 1 BioNTech SE $9,960.30 04/23/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020475
Principal investigator 1 BioNTech SE $8,647.05 04/23/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020477
Principal investigator 1 Merck Sharp & Dohme LLC $4,500.00 04/16/2025 Non-covered Recipient Entity
Millennium Research & Clinical Development
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927561
Principal investigator 1 BioNTech SE $25,824.70 04/15/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020473
Principal investigator 1 BioNTech SE $450.00 04/10/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020493
Principal investigator 1 BioNTech SE $3,000.00 04/10/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020495
Principal investigator 1 BioNTech SE $3,500.00 04/10/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020497
Principal investigator 1 BioNTech SE $12,000.00 04/10/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020499
Principal investigator 1 BioNTech SE $2,903.00 04/08/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020501
Principal investigator 1 BioNTech SE $6,448.00 04/08/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020503
Principal investigator 1 BioNTech SE $9,351.00 04/08/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-07 No dispute reported 06/30/2026 1249020505
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,750.00 04/02/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH & DEVELOPMENT, LLC
A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON No dispute reported 06/30/2026 1185554270
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,155.00 03/28/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase 1b2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan T-DXd Monotherapy and Combinations in Adult Participants with HER2 Overexpressing Gastric Cancer DESTINY-Gastric03 No dispute reported 06/30/2026 1185554244
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,460.00 03/26/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185554240
Principal investigator 1 BioNTech SE $3,500.00 02/25/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020665
Principal investigator 1 BioNTech SE $450.00 02/25/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020667
Principal investigator 1 BioNTech SE $3,000.00 02/25/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020669
Principal investigator 1 BioNTech SE $12,000.00 02/25/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-06 No dispute reported 06/30/2026 1249020671
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16,500.00 02/13/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233741026
Principal investigator 1 BioNTech SE $3,950.00 02/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-03 No dispute reported 06/30/2026 1249020659
Principal investigator 1 BioNTech SE $3,000.00 02/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-03 No dispute reported 06/30/2026 1249020661
Principal investigator 1 BioNTech SE $12,000.00 02/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC
BNT327-03 No dispute reported 06/30/2026 1249020663
Principal investigator 1 BioNTech SE $72.73 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014125
Principal investigator 1 BioNTech SE $42.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014127
Principal investigator 1 BioNTech SE $98.10 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014129
Principal investigator 1 BioNTech SE $330.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014131
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-06 No dispute reported 06/30/2026 1249014133
Principal investigator 1 BioNTech SE $85.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014135
Principal investigator 1 BioNTech SE $330.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014153
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-06 No dispute reported 06/30/2026 1249014155
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014157
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014159
Principal investigator 1 BioNTech SE $85.00 02/01/2025 Non-covered Recipient Entity
Millennium Research and Clinical Development, LLC
BNT327-03 No dispute reported 06/30/2026 1249014161
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,452.40 01/31/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185554248
Principal investigator 1 AstraZeneca UK Limited $23,793.00 01/31/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185554262
Principal investigator 1 AstraZeneca Pharmaceuticals LP $176,075.11 01/24/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185554268
Principal investigator 1 AstraZeneca UK Limited $119,165.34 01/15/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY No dispute reported 06/30/2026 1185554242
Principal investigator 1 AstraZeneca Pharmaceuticals LP $139,604.24 01/13/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185554254
Principal investigator 1 AstraZeneca Pharmaceuticals LP $62,711.39 01/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185554246
Principal investigator 1 AstraZeneca Pharmaceuticals LP $91,396.76 01/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185554252
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,436.43 01/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185554258